PTEO News 0.0350 Proteo Inc (PTEO)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Proteo Inc (PTEO) 0.0350 $PTEO

Lung Transplantation - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhlntx/lung) has announced the addition of the "Lung Transplantation - Pipeline Review, H1 2014" report to their offering. 'Lung Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. Scope - A snapshot of the global therapeutic scenario for Lung Transplantation. - A review of the Lung Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lung Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Lung Transplantation Overview Therapeutics Development Pipeline Products for Lung Transplantation - Overview Pipeline Products for Lung Transplantation - Comparative Analysis Lung Transplantation - Therapeutics under Development by Companies Lung Transplantation - Pipeline Products Glance Late Stage Products Early Stage Products Lung Transplantation - Companies Involved in Therapeutics Development Lung Transplantation - Therapeutics Assessment Drug Profiles cyclosporine - Drug Profile EZ-2053 - Drug Profile Elafin - Drug Profile Respiratory and Inflammatory Diseases Program - Drug Profile VR-909 - Drug Profile Lung Transplantation - Recent Pipeline Updates Lung Transplantation - Product Development Milestones Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Quark Pharmaceuticals, Inc. Vectura Group plc Proteo, Inc. APT Pharmaceuticals, Inc. (Inactive) Neopharm Ltd. For more information visit http://www.researchandmarkets.com/research/lhlntx/lung About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research Report: Cystic Fibrosis - Pipeline Review, H2 2013
M2 - Mon Nov 11, 3:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/wfwrck/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Cystic Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cystic Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. Scope - A snapshot of the global therapeutic scenario for Cystic Fibrosis. - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cystic Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Genzyme Corporation Johnson & Johnson Boehringer Ingelheim GmbH GlaxoSmithKline plc Gilead Sciences, Inc. Vectura Group plc Novartis AG Axcan Pharma Inc. Chiesi Farmaceutici SpA Pfizer Inc. Vertex Pharmaceuticals Incorporated Zambon Group S.p.A. Optimer Pharmaceuticals, Inc. PARI Pharma GmbH Hollis-Eden Pharmaceuticals, Inc. Pharmaxis Ltd. CSL Limited Protalix BioTherapeutics, Inc. Lipoxen PLC Galapagos NV Kamada Ltd. Proteo, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/wf...c_fibrosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Proteo, Inc. / Proteo Biotech AG: Patient Recruitment and Treatment in Elafin CABG Phase II Clinical Trial Completed
Business Wire - Fri Nov 08, 4:56AM CST
Proteo, Inc. (OTCQB TEO) and its wholly-owned subsidiary Proteo Biotech AG today announced that the NHS Lothian's Edinburgh Heart Centre has successfully completed patient recruitment and treatment for the Phase II clinical trial (EMPIRE study) with Proteo's drug candidate Elafin for prevention of myocardial injury after coronary artery bypass surgery (CABG). According to plan top-line results from this trial are expected to be announced in the first quarter of 2014.

Research Report: Pulmonary Arterial Hypertension - Pipeline Review, H2 2013
M2 - Fri Nov 08, 3:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/z58nv7/pulmonary) has announced the addition of the "Pulmonary Arterial Hypertension - Pipeline Review, H2 2013" report to their offering. 'Pulmonary Arterial Hypertension - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Arterial Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension. Scope - A snapshot of the global therapeutic scenario for Pulmonary Arterial Hypertension. - A review of the Pulmonary Arterial Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pulmonary Arterial Hypertension pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned United Therapeutics Corporation Merck & Co., Inc. Novartis AG Actelion Ltd Dong-A Pharmaceutical Co., Ltd. Nippon Shinyaku Co., Ltd. Bayer AG Celladon Corporation Arena Pharmaceuticals, Inc. Cytokinetics, Inc Pluristem Therapeutics Inc. Proteo, Inc. Aires Pharmaceuticals, Inc. Cardioxyl Pharmaceuticals, Inc. Mondobiotech Holding AG PhaseBio Pharmaceuticals, Inc. Asahi Kasei Pharma Adeona Pharmaceuticals, Inc. Lacer, S.A. Ikaria Inc. Bial - Portela & Ca, S.A. Northern Therapeutics, Inc. miRagen Therapeutics, Inc. PharmaIN Corporation For more information visit http://www.researchandmarkets.com/research/z58nv7/pulmonary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Market Research: Ischemia Reperfusion Injury - Pipeline Review, H2 2013
M2 - Thu Nov 07, 2:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/zdcd6h/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H2 2013" report to their offering. 'Ischemia Reperfusion Injury - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ischemia Reperfusion Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury. Scope - A snapshot of the global therapeutic scenario for Ischemia Reperfusion Injury. - A review of the Ischemia Reperfusion Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ischemia Reperfusion Injury pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Pharming Group N.V. BioLineRx, Ltd. Proteo, Inc. Prolong Pharmaceuticals Trophos SA Curatis Pharma GmbH Alligator Bioscience AB Opsona Therapeutics Ltd. PledPharma AB Omeros Corporation Bolder Biotechnology, Inc. ADIENNE Pharma & Biotech Dr. Franz Kohler Chemie GmbH GENEXTRA S.p.A. ToleroTech Inc. Ischemix For more information visit http://www.researchandmarkets.com/research/zdcd6h/ischemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

OTC Signal Daily Stock Watch - Proteo Inc. (OTCQB: PTEO)
WorldStockWire - Tue Sep 03, 9:30PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com

Allergies - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Allergies
M2 - Mon Sep 02, 12:23PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2kfdwp/allergies) has announced the addition of the "Allergies - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Allergies - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergies, complete with latest updates, and special features on late-stage and discontinued projects. Allergies - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Allergies. - A review of the Allergies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergies pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - ALK-Abello A/S - ANERGIS SA - Actelion Ltd - ActogeniX NV - Antigen Express, Inc. - AstraZeneca PLC - BioLineRx, Ltd. - Biomay AG - Biotec Pharmacon ASA - Clarassance, Inc. - Cytos Biotechnology AG - Dainippon Sumitomo Pharma Co., Ltd. - EpiVax, Inc. - GlaxoSmithKline plc - Idera Pharmaceuticals, Inc. - Immune Design Inc. - ImmunoFrontier, Inc. - Immupharma Plc - Indus Biotech Private Limited - IntelGenx Technologies Corp. - Interprotein Corporation - Japan Tobacco Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Novartis AG - Proteo, Inc. - RaQualia Pharma Inc. - SIFI S.p.A - Shionogi & Co., Ltd. - SuppreMol GmbH - ToleroTech Inc. - United Biomedical, Inc. - Vaxine Pty Ltd - Viromed Co., Ltd. - Xencor, Inc. For more information visit http://www.researchandmarkets.com/research/2kfdwp/allergies About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Lung Transplantation - Pipeline Review, H1 2013
M2 - Fri Apr 12, 5:28AM CDT
Research and Markets has announced the addition of the "Lung Transplantation - Pipeline Review, H1 2013" report to their offering. 'Lung Transplantation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. Scope - A snapshot of the global therapeutic scenario for Lung Transplantation. - A review of the Lung Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lung Transpl

Proteo, Inc. /Proteo Biotech AG: FDA Grants Orphan Drug Designation to Elafin for Prevention of Inflammatory Complications of Transthoracic Esophagectomy
Business Wire - Wed Mar 20, 12:41PM CDT
Proteo, Inc. (OTCQB: PTEO) and its wholly-owned subsidiary Proteo Biotech AG announced today: The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Elafin for the prevention of inflammatory complications of transthoracic esophagectomy.

Proteo, Inc. / Proteo Biotech AG: FDA grants Proteo Orphan Drug Designation to Elafin for the treatment of pulmonary arterial hypertension
Business Wire - Thu Jan 10, 7:00AM CST
Proteo, Inc. (OTCQB: PTEO) and its wholly-owned subsidiary Proteo Biotech AG announced today: The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Elafin for the treatment of pulmonary arterial hypertension.

Cystic Fibrosis - Pipeline Review, H2 2012
M2 - Tue Jan 08, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/p9x3z6/cystic_fibrosis) has announced the addition of Global Markets Direct's new report "Cystic Fibrosis - Pipeline Review, H2 2012" to their offering. 'Cystic Fibrosis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cystic Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. Scope - A snapshot of the global therapeutic scenario for Cystic Fibrosis. - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monothe
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vail Resorts Bets on Music to Deepen Epic Pass Demand

Updated Category News Views 119

A bass drop at 11,000 feet is not merely a party trick when you run 42 mountain resorts. Vail Resorts is putting live music, après programming and destination events squarely beside skiing and riding for winter 2026-27, and the business logic is pretty plain: give people another reason to buy early, stay longer and return with friends. For investors watching MTN, this is...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 120

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
LGT Middle East Win Highlights Patient Private Banking

Updated Category News Views 166

A trophy in Dubai is not a balance sheet, but it can be a useful calling card when the clientele measures relationships in decades rather than quarters. LGT Middle East was named Best Pure Play Private Bank at the WealthBriefing MENA Awards 2026, at a ceremony held in Dubai on November 18. For a family-owned wealth manager working with Middle Eastern families, that sort...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 123

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
New York's $1.2M Prison Abuse Deal Raises State Stakes

Updated Category News Views 30

One courtroom result can expose a whole warehouse of institutional neglect, and this one lands with a grim thud. New York has agreed to pay $1.2 million to resolve a claim involving sexual assault by a former corrections officer at Bayview Correctional Facility in Manhattan. The settlement came after a two-week Adult Survivors Act bellwether trial concluded on November 17...

Continue Reading
Africa’s Digital Leap Still Has a 64% Usage Problem

Updated Category News Views 100

A continent can be blanketed in signal and still feel digitally stranded. That is the stubborn fact sitting inside the GSMA Digital Africa Index 2026: mobile broadband reaches 92% of Africa’s population, while only 28% use mobile internet on their own devices. The 64% usage gap is not a rounding error or a tidy policy footnote. It is the whole unfinished job. From an...

Continue Reading
SciBase Sets Its 2027 AGM Nominating Committee Early

Updated Category News Views 94

Four names on a committee roster rarely make anyone pound the table, and they should not. Still, SciBase Holding has put an important bit of corporate housekeeping in place for its 2027 Annual General Meeting: the nominating committee that will handle shareholder-facing governance work ahead of the May 20 meeting in Stockholm. For a small listed medical-technology...

Continue Reading
Ajman Forum Puts Trust at the Center of Crisis Media

Updated Category News Views 82

Rumours do not wait politely for a communications team to finish its meeting. That plain reality sat underneath Abdulla bin Mohammed bin Butti Al Hamed's keynote at Ajman Media Forum 2026, and it is a tougher point than the usual talk about reach, engagement, or flashy new technology. In a crisis, an information vacuum gets filled fast, usually by somebody with no...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 145

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Shenzhen Three-Way Summit Puts Stability to the Test

Updated Category News Views 153

Three nuclear powers sharing a room in Shenzhen is the sort of headline that makes every risk desk sit upright, even when the paperwork remains thin. CGTN reports that Chinese President Xi Jinping, Russian President Vladimir Putin and U.S. President Donald Trump met on November 19, 2026, in an unprecedented trilateral summit and issued a Declaration toward Peace. That is...

Continue Reading

Top 5 Most Recently Viewed Articles

bioAffinity Technologies Launches $2.66 Million Funding Initiative

Updated Category News Views 207

Exciting Funding Development Announced by bioAffinity Technologies bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a pioneering company in the field of biotechnology, has announced an exciting funding development that is set to enhance its capability in the noninvasive detection of early-stage cancer. The company has entered into a securities purchase agreement with...

Continue Reading
Wendy's Expands Its Franchise Opportunities in Tijuana

Updated Category News Views 132

Wendy's Expands Its Franchise Opportunities in Tijuana The Wendy's Company is seeking passionate and experienced franchise partners as it intensifies its expansion strategy in Tijuana and the larger Baja California region. With the aim to develop new restaurant locations, Wendy's recognizes the potential to thrive in this vibrant market. The company has planned a...

Continue Reading
Insights into Upcoming Earnings for Vail Resorts

Updated Category News Views 215

Anticipating Vail Resorts' Earnings Report Vail Resorts (NYSE: MTN) is gearing up to release its latest quarterly earnings report, and the anticipation among investors is palpable. This upcoming announcement will shed light on the company's financial performance, and many are eagerly awaiting the results. Analyst Earnings Estimates Forecasts suggest that Vail Resorts...

Continue Reading
Creatv Bio's Innovative Blood Test for Colorectal Cancer Trials

Updated Category News Views 115

Revolutionary LifeTracDx® Blood Test in Colorectal Cancer Trials Creatv Bio, a division of Creatv MicroTech, Inc., is taking significant strides in the realm of cancer diagnostics. The introduction of their LifeTracDx® blood test in collaboration with CytoDyn Therapeutics Corporation marks a promising development in assessing patient responses to innovative treatments....

Continue Reading
Freedom Mortgage Celebrates 9 Years of Excellence with STAR Award

Updated Category News Views 212

Freedom Mortgage Earns Prestigious Recognition Again Freedom Mortgage has once again made headlines by receiving the Fannie Mae Servicer Total Achievement and Rewards™ (STAR™) Performer Award for an impressive ninth consecutive year. This accolade highlights Freedom Mortgage as a leading performer in the mortgage servicing industry, particularly for its remarkable...

Continue Reading